Cargando…

Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma

BACKGROUND: KRAS-mutant lung adenocarcinomas (LUADs) are heterogeneous and frequently occur in smokers. The heterogeneity of KRAS-mutant LUAD has been an obstacle for the drug discovery. METHODS: We integrated multiplatform datatypes and identified two corresponding subtypes in the patients and cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Ke, Guo, Jintao, Liu, Kuai, Fan, Peiyang, Zeng, Yuanyuan, Xu, Chaoqun, Zhong, Jiaxin, Li, Qiyuan, Zhou, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Research paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197714/ https://www.ncbi.nlm.nih.gov/pubmed/30268834 http://dx.doi.org/10.1016/j.ebiom.2018.09.034

Ejemplares similares

Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma
por: Best, Sarah A., et al.
Publicado: (2019)

Distinct metabolic preference of atypical KRAS mutant
por: Cheong, Heesun
Publicado: (2020)

Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma
por: Wang, Qi, et al.
Publicado: (2023)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations
por: Hu, Yan, et al.
Publicado: (2020)

Cis- and Trans-Acting Expression Quantitative Trait Loci of Long Non-Coding RNA in 2,549 Cancers With Potential Clinical and Therapeutic Implications
por: Li, Wenzhi, et al.
Publicado: (2020)

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors
por: Baldelli, Elisa, et al.
Publicado: (2015)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer
por: Zhang, Jiaxin, et al.
Publicado: (2022)

Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer
por: Gao, Liyuan, et al.
Publicado: (2022)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas
por: Li, Jinyu, et al.
Publicado: (2016)

SMARCA4 mutations in KRAS‐mutant lung adenocarcinoma: a multi‐cohort analysis
por: Liu, Liang, et al.
Publicado: (2020)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Identification of Distinct Molecular Subtypes of Endometrioid Adenocarcinoma
por: Lei, Jia, et al.
Publicado: (2021)

The KRAS-Mutant Consensus Molecular Subtype 3 Reveals an Immunosuppressive Tumor Microenvironment in Colorectal Cancer
por: Tanjak, Pariyada, et al.
Publicado: (2023)

BRAF-Mutant Pulmonary Langerhans Cell Histiocytosis Mimicking Recurrence of Early-Stage KRAS-Mutant Lung Adenocarcinoma
por: Alden, Stephanie L., et al.
Publicado: (2020)

Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications
por: Pathak, Ranjan, et al.
Publicado: (2021)

The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations
por: Zheng, Difan, et al.
Publicado: (2016)

Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities
por: Kerr, Emma, et al.
Publicado: (2016)

Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer
por: Knickelbein, Kyle, et al.
Publicado: (2014)

Therapeutic Approach of KRAS Mutant Tumours by the Combination of Pharmacologic Ascorbate and Chloroquine
por: Kapuy, Orsolya, et al.
Publicado: (2021)

Survivin knockdown induces senescence in TTF-1-expressing, KRAS-mutant lung adenocarcinomas
por: Sumi, Toshiyuki, et al.
Publicado: (2018)

PLCγ1 suppression promotes the adaptation of KRAS-mutant lung adenocarcinomas to hypoxia
por: Saliakoura, Maria, et al.
Publicado: (2020)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016)

Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma
por: Deng, Haoyu, et al.
Publicado: (2019)

Small molecular inhibitors for KRAS-mutant cancers
por: Wu, Xuan, et al.
Publicado: (2023)

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
por: Bournet, Barbara, et al.
Publicado: (2016)

KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
por: Bhattacharya, Saveri, et al.
Publicado: (2015)

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer
por: Wang, Haiyun, et al.
Publicado: (2019)

Exploiting macropinocytosis for drug delivery into KRAS mutant cancer
por: Liu, Huiqin, et al.
Publicado: (2022)

A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS
por: Zhang, Xiang-Hua, et al.
Publicado: (2013)

Molecular profiling identifies distinct subtypes across TP53 mutant tumors
por: Chen, Xin, et al.
Publicado: (2022)

Exonic variants undergoing allele-specific selection in cancers
por: Li, Qiyuan, et al.
Publicado: (2021)

Submucosal micropapillary adenocarcinoma of the sigmoid colon: A distinct and aggressive subtype of adenocarcinoma
por: Limaiem, Faten, et al.
Publicado: (2023)

The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer
por: Diehl, J. Nathaniel, et al.
Publicado: (2021)

Exposure to Tobacco Smoking Induces a subset of Activated Tumor-resident Tregs in Non-Small Cell Lung Cancer
por: Hu, Yudi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tg5lc6fu7q4ookmhpousl05v4n